RealFeedApp MTX325 blocks USP30 to clear damaged mitochondria
Mission Therapeutics initiated a Phase 1b study with the first patient using MTX325, a first-in-class oral inhibitor of the USP30 enzyme. The drug aims to enhance mitophagy by clearing damaged mitochondria in the brain.
- Field
- ageing and longevity
- What they did
- Researchers have started a Phase 1b clinical trial of the drug MTX325 on the first patient with Parkinson's disease. The medication blocks the enzyme USP30, which prevents cells from removing damaged mitochondria (the energy power plants inside cells).
- Why it matters
- The goal is to test whether improving the clearance of damaged mitochondria can preserve cell health and reduce brain inflammation, potentially slowing the progression of the disease.
#parkinson's disease#mitophagy#usp30#mission therapeutics#phase 1b
